{
    "root": "36366a0a-f6b5-5ada-e063-6394a90a98dc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Warfarin Sodium",
    "value": "20250528",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "WARFARIN SODIUM",
            "code": "6153CWM0CL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10034"
        }
    ],
    "indications": {
        "text": "warfarin sodium tablets indicated : prophylaxis treatment venous thrombosis extension , pulmonary embolism ( pe ) . prophylaxis treatment thromboembolic complications associated atrial fibrillation ( af ) and/or cardiac valve replacement . reduction risk death , recurrent myocardial infarction ( myocardial infarction ) , thromboembolic events stroke systemic embolization myocardial infarction . limitations warfarin sodium tablets direct effect established thrombus , reverse ischemic tissue damage . thrombus occurred , however , goals anticoagulant treatment prevent extension formed clot prevent secondary thromboembolic complications may result serious possibly fatal sequelae .",
        "doid_entities": [
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "pulmonary embolism (DOID:9477)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9477"
            },
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            },
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "individualize dosing regimen patient , adjust based inr response . ( 2.1 , 2.2 ) knowledge genotype inform initial dose selection . ( 2.3 ) monitoring : obtain daily inr determinations upon initiation stable therapeutic range . obtain subsequent inr determinations every 1 4 weeks . ( 2.4 ) review conversion instructions anticoagulants . ( 2.8 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "warfarin sodium tablets usp , 5 mg available peach , capsule-shaped , biconvex scored tablets , debossed tv/5 scored side 1721 side containing 5 mg warfarin sodium , usp , packaged ndc : 70518-0253-00 ndc : 70518-0253-01 packaging : 30 1 blister pack packaging : 30 1 bottle plastic dispense tight , light-resistant container defined usp , child-resistant closure ( required ) . protect light . keep tightly closed . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . special handling procedures proper handling disposal potentially hazardous drugs considered . guidelines subject published [ references ( 15 ) ] . pharmacy personnel pregnant avoid exposure crushed broken tablets [ ( 8.1 ) ] . keep medications reach children . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "warfarin sodium contraindicated : pregnancy warfarin sodium contraindicated women pregnant except pregnant women mechanical heart valves , high risk thromboembolism [ ( 5.7 ) ( 8.1 ) ] . warfarin sodium cause fetal harm administered pregnant woman . warfarin sodium exposure pregnancy causes recognized pattern major congenital malformations ( warfarin embryopathy fetotoxicity ) , fatal fetal hemorrhage , increased risk spontaneous abortion fetal mortality . warfarin sodium used pregnancy patient becomes pregnant taking , patient apprised potential hazard fetus [ ( 8.1 ) ] . warfarin sodium contraindicated patients : hemorrhagic tendencies blood dyscrasias recent contemplated surgery central nervous system eye , traumatic surgery resulting large open surfaces [ ( 5.8 ) ] bleeding tendencies associated : \u2212 active ulceration overt bleeding gastrointestinal , genitourinary , respiratory tract \u2212 central nervous system hemorrhage \u2212 cerebral aneurysms , dissecting aorta \u2212 pericarditis pericardial effusions \u2212 bacterial endocarditis threatened abortion , eclampsia , preeclampsia unsupervised patients conditions associated potential high level non-compliance spinal puncture diagnostic therapeutic procedures potential uncontrollable bleeding hypersensitivity warfarin components product ( e.g . , anaphylaxis ) [ ( 6 ) ] major regional lumbar block anesthesia malignant hypertension",
    "indications_original": "Warfarin sodium tablets are indicated for:\n                  \n                     Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE).\n                     Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.\n                     Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.\n                  \n                  \n                     Limitations of Use\n                  \n                  Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.",
    "contraindications_original": "Individualize dosing regimen for each patient, and adjust based on INR response. ( 2.1 , 2.2 ) Knowledge of genotype can inform initial dose selection. ( 2.3 ) Monitoring: Obtain daily INR determinations upon initiation until stable in the therapeutic range. Obtain subsequent INR determinations every 1 to 4 weeks. ( 2.4 ) Review conversion instructions from other anticoagulants. ( 2.8 )",
    "warningsAndPrecautions_original": "Warfarin sodium tablets USP, 5 mg are available as peach, capsule-shaped, biconvex scored tablets, debossed with TV/5 on the scored side and 1721 on the other side containing 5 mg warfarin sodium, USP, packaged in\n                  NDC: 70518-0253-00\n                  NDC: 70518-0253-01\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).\n                  Protect from light. Keep tightly closed.\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].\n                  Special Handling\n                  Procedures for proper handling and disposal of potentially hazardous drugs should be considered. Guidelines on this subject have been published [see References (15)].\n                  Pharmacy and clinical personnel who are pregnant should avoid exposure to crushed or broken tablets [see Use in Specific Populations (8.1)].\n                  KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Warfarin sodium is contraindicated in:\n                  \n                     Pregnancy\n                  \n                  Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism \n       \n \n  [see Warnings and Precautions (\n        \n  \n   5.7) and Use in Specific Populations (\n        \n  \n   8.1)]\n       \n \n  . Warfarin sodium can cause fetal harm when administered to a pregnant woman. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus \n       \n \n  [see Use in Specific Populations (\n        \n  \n   8.1)]\n       \n \n  . \n      \n\n \n                  Warfarin sodium is contraindicated in patients with:\n                  \n                     Hemorrhagic tendencies or blood dyscrasias \n                     Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces \n        \n  \n   [see Warnings and Precautions (\n         \n   \n    5.8)]\n        \n  \n   \n                     \n                     Bleeding tendencies associated with:\n        \n  \n   \u2212 Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract \n        \n  \n   \u2212 Central nervous system hemorrhage \n        \n  \n   \u2212 Cerebral aneurysms, dissecting aorta \n        \n  \n   \u2212 Pericarditis and pericardial effusions \n        \n  \n   \u2212 Bacterial endocarditis \n       \n \n  \n                     Threatened abortion, eclampsia, and preeclampsia \n                     Unsupervised patients with conditions associated with potential high level of non-compliance \n                     Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding \n                     Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) \n        \n  \n   [see Adverse Reactions (\n         \n   \n    6)] \n        \n  \n   \n                     \n                     Major regional or lumbar block anesthesia \n                     Malignant hypertension",
    "drug": [
        {
            "name": "Warfarin Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10034"
        }
    ]
}